Epidemiology of prostate cancer;Epidemiología del cáncer de próstata

Clinical and Translational Oncology

Volumn 3, Issue 1, 2001, Pages 11-21

  Bernal, Laura Súchil ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Epidemiology; Prostate cancer

Indexed keywords

EID: 84873675797     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Levi F, La Vecchia C, Randimbison L, Erler G, Te VC, Franceschi S. Incidence, mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, 1974-1994. Ann Oncol 1998; 9: 31-35.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-841.
3. Whitmore WF. Localized prostatic cancer: management and detection issues. Lancet 1994; 343: 1.263-1.67.
4. Merril R, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology 1997; 8: 126-131.
5. Silverberg BS, Lubera JA. Cancer statistics, 1989. Cancer 1989; 39: 3-20.
6. Zaridze DG, Boyle P, Smans M. International trends in prostatic cancer. Int J Cancer 1984; 33: 223-230.
7. Compendio del Registro Histopatológico de Neoplasias en México. Morbilidad y Mortalidad 1998. DGE, SSA. 2000.
8. Parkin DM, Stjernsward J, Muir CS. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 1984; 62: 163-182.
9. Von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins M. American Cancer Society Guidelines for the early detection of prostate cancer. Cancer 1997; 80: 1.805-1.07.
10. Miller BA, Ries LAG, Hankey BF, et al. SEER Cancer Statistics Review: 1973-1990. IH Pub N.0 93-2789. ethesda, National Cancer Institute, 1993.
11. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. New York: Oxford University Press, 1981.
12. Potosky AL, Miller B, Albertsen P, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-552.
13. Catalona WJ, Smith DS, Ratliff T, et al. Detection of organ- confines prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-954.
14. Muir C, Waterhouse J, Mack T, et al. Cancer Incidence in Five Continents. Vol V, International Agency for Research on Cancer, 1987.
15. Reynolds T. Stat bite: prostate cancer mortality by race/ ethnic group, 1977-1983. Natl Cancer Inst 1992; 84: 997.
16. Bernstein L, Ross R. Cancer in Los Angeles County. A portrait of incidence and mortality 1972-1987. os Angeles: University of Southern California Press, 1995.
17. Lilienfield AM, Levin ML, Kessler II. Cancer in the United States. APHA Monograph. Cambridge: Harvard University Press, 1972.
18. Seidman H. Cancer death rates by site and sex for religious and socioeconomic groups in New York City. Environ Res 1970; 3: 235-250.
19. Ernster VL, Winkelstein W, Selvin S, et al. Race, socioeconomic status and prostatic cancer. Cancer Treat Rep 1977; 61: 187-191.
20. Hoover R, Mason TJ, McKay FW, et al. Geographic patterns of cancer mortality in the United States. En: Fraumeni JF, ed. Persons at high risk of cancer. New York: Academic Press, 1988; 343-360.
21. Richardson INM. Prostatic cancer and social class. Br J Prev Med 1965; 19: 140-142.
22. Baquet CR, Horm JW, Gibbs T, et al. Socieconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 1991; 83: 551-557.
23. Hakki Si, Chisholm GD, Skeet RG. Social class and carcinoma of the prostate. Br. J Urol 1979; 51: 393-396
24. Newell GR, Pollack ES, Spitz MR, et al. Incidence of prostate cancer and marital status. J Natl Cancer Inst 1987; 79: 259-262.
25. Clemmensen J. Statitstical studies in the aetiology of malignant neoplasms APMS 1969; 209 (Supl): 1-171.
26. Ernster VL, Sacks ST, Selvin S, et al. Cancer incidence by marital status: US Third National Cancer Survey. J Natl Cancer Inst 1979; 63: 567-585.
27. Waterhouse JAH, Muir CS, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol IV, IARC Sci Pub 42. Lyon: International Agency for Research on Cancer, 1982.
28. Lyon JL, Klauber MR, Gardner JE, et al. Cancer incidence in mormons and non-mormons in Utah, 1996- 1970. Engl J Med 1976; 294: 129-133.
29. Phillips RL. Role of life-style and dietary habits in risk of cancer among Seventh-Day Adventists. Cancer Res 1975; 35: 3.513-3.22.
30. Phillips RL, Snowdon DA. Association of meat and coffee use with cancer of the large bowel, breast, and prostate among Seventh-Day Adventists: preliminary results. Cancer Res 1983; 43: 2.403s-2.408s.
31. Huggins C, Hodges CV. Studies on prostatic cancer: effect of castration, of oestrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
32. Henderson BE, Ross RK, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3.232-3.39
33. Coffey DS. Physiological control of prostatic growth. An overview. En: Prostate cancer. UICC Technical report series, Vol 48. Geneva: International Union Against Cancer, 1979.
34. Griffiths R, Davies P, Harper ME, et al. The etiology and endocrinology of prostatic cancer. En: Rose DP, ed. Endocrinology in cancer. Boca Raton, FL: CRC Press Inc, 1979.
35. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928-934.
36. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994; 331: 996-1.04.
37. Ghanadian R, Puah CM, O'Donoghue EPN. Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 1979; 39: 696-699.
38. Ahluwalia B, Jackson MA, Jones GW, et al. Blood hormone profiles in prostate cancer patients in high risk and low risk populations. Cancer 1981; 48: 2.267-2.73.
39. Drafta D, Proca E, Zamfir V, et al. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 1982; 17: 689-693.
40. Wright F, Poizat R, Bongini M, et al. Decreased urinary (5 alpha-androstane-3 alpha, 17-diol) glucuronide excretion in patients with benign prostatic hypertrophy. Clin Endocrinol Metab 1985; 60: 294-298.
41. Zumoff B, Levin J, Stain GW, et al. Abnormal levels of plasma hormones in men with prostate cancer: evidence towards a «two-disease» theory. Prostate 1982; 3: 579-588.
42. Harper ME, Peeling WB, Cowley T, et al. Plasma steroid and protein hormone concentrations in patients with prostatic carcinoma, before and during estrogen therapy. Acta Endocrinol 1976; 81: 409-426.
43. Bartsch W, Horst HJ, Becker H, et al. Sex hormone binding globulin-binding capacity, testorerone, 5-alpha dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. cta Endocrinol 1997; 85: 650-654.
44. Hulka BS, Hammond JE, DiFerdinandi G, et al. Serum hormone levels among patients with prostatic carcinoma of benign prostatic hyperplasia and clinic controls. Prostate 1987; 11: 171-182.
45. Hammond GL, Kontturi M, Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 1978; 9: 113-121.
46. Meikle AW, Stanish WM. Familial prostatic cancer risk and low testosterone. J Clin Endocrinol Metab 1982; 54: 1.104-1.08.
47. Rose DP. The biochemical epidemiology of prostatic carcinoma. En: Ip C, Birt DF, Rogers AE, Mettlin C, eds. Dietary fat and cancer. New York: Alan R Liss, 1986, 43-68.
48. Dai Ws, Kuller LH, LaPorte RE, et al. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol 1981; 114: 804-816.
49. Delsypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, lifestyle, residence, diet and activity. J Clin Endocrinol Metab 1984; 59: 955-962.
50. Ross RK, Bernstein L, Judd H, et al. Serum testosterone levels in young black and white men. J Natl Cancer Inst 1986; 76: 45-48.
51. Ellis L, Nyborg H. Racial/ethnic variations in male testosterone levels: a probable contributor to group differences in health. Steroids 1992; 57: 72-75.
52. Pike MC, Krailo MD, Henderson BE, et al. Hormonal risk factors «breast tissue age» and the age-incidence of breast cancer. Nature 1983; 3030: 767-770.
53. Henderson BE, Bernstein L, Ross RK, et al. The early in utero oestrogen and testosterone environment of blacks and whites: Potential effects on male offspring. Br J Cancer 1988; 57: 216-218.
54. Ross RK, Henderson BE. Do dietary and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 1994; 86: 252-254.
55. Ranniko KS, Aldercreutz H, Haapianinen R. Urinary oestrogen excretion in benign prostatic hyperplasia and prostate cancer. Br J Urol 1989; 64: 172-175.
56. Nomura A, Heilbrun LJ, Stemmerman GN, et al. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988; 48: 3.515-3.17.
57. Keenan EJ, Kemp DE, Ramsey EE, et al. Specific binding of prolactin by the prostate gland of the rat and man. J Urol 1979; 122: 43-46.
58. Grayhack JT. Pituitary factors influencing growth of the prostate. Natl Cancer Monogr 1963; 12: 189-199.
59. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha reductase activity and risk of prostate cancer among Japanese and US white and black males. ancet 1992; 339: 887-890.
60. Lookingbill DP, Demers LM, Wang C, et al. Clinical and biological parameters of androgen action in normal healthy caucasian versus chinese subjects. J Clin Endocrinol Metab 1991; 72: 1.242-1.48.
61. Brawley OW, Ford LG, Thompson I, et al. 5-alpha reductase inhibition and prostate cancer prevention. ancer Epidemiol Biomarkers 1994; 3: 177-182.
62. Peto R, Doll R, Buckley JD, et al. Can dietary beta-carotene material reduce human cancer rates? Nature 1981; 290: 201-208.
63. Bates CJ. Vitamin A. Lancet 1995; 345: 31-35.
64. Peto R. The marked differences between carotenoids and retinoids: methodological implications for biochemical epidemiology. Cancer Surv 1983; 2: 327-340.
65. Chaproniere DM, Weber MM. Dexamethasone and retinol acetate similar inhibit and stimulate EGF or insulin- induced proliferation of prostatic epithelium. J Cell Physiol 1985; 122: 249-253.
66. Hirayama T. Epidemiology of prostate cancer with special reference to the role of diet. Natl Cancer Inst Monogr 1979; 53: 149-152.
67. Paganini-Hill A, Chao A, Ross RK, et al. Vitamin A, B-carotene and the risk of cancer. A prospective study. J Natl Cancer Inst 1987; 79: 443-448.
68. Hsing WA, Mclaughlin JK, Schuman LM, et al. Diet, tabacco use and fatal prostate cancer: results from the Lutheran Brotherhood cohort study. Cancer Res 1990; 50: 6.836-6.40.
69. Mills PK, Beeson L, Phillips RL, et al. Cohort study of diet, lifestyle, and prostate cancer in adventist men. Cancer 1989; 64: 598-604.
70. Kolonel LN, Hankin JH, Yoshizawa CN. Vitamin A and prostate cancer in elderly men: enhancement of risk. Cancer Res 1987; 47: 2.982-2.85.
71. Heshmat NY, Kaul L, Kovi J, et al. Nutrition and prostate cancer. A case-control study. Prostate 1985; 6: 7-17.
72. Graham S, Haughey B, Marshall J, et al. Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst 1983; 70: 687-692.
73. Mettlin C, Selenskas S, Natarajan N, et al. Beta-carotene and animal fats and their relationship to prostate cancer risk. A case-control study. Cancer 1989; 64: 605-612.
74. Kark JD, Smith AH, Switzer BR, et al. Serum vitamin A (retinol) and cancer incidence in Evans County, Georgia. J Natl Cancer Inst 1981; 66: 7-16.
75. Willet WC, Polk BF, Underwood BA, et al. Relation of serum vitamins A and E, and carotenoids to the risk of cancer. N Engl J Med 1984; 310: 430-434.
76. Hsing WA, Comstock GW, Abbey H, et al. Serologic precursors of cancer, retinol, carotenoids and tocopherol and risk of prostate cancer. J Natl Cancer Inst 1990; 82: 941-946.
77. Reichman ME, Hayes RB, Ziegler RG, et al. Serum vitamin A and subsequent development of prostate cancer in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 1990; 50: 2.311-2.15.
78. Hayes RB, Bogdanovicz FAT, Schroeder FH, et al. Serum retinol and prostate cancer. Cancer 1988; 62: 2.021-2.26.
79. Berg JW. Can nutrition explain the pattern of international epidemiology of hormone-dependent cancers? Cancer Res 1975; 35: 3.345-3.50.
80. Hill PB, Wynder EL. Effect of vegetarian diet and dexamethasone on plasma prolactin, testosterone and dehydroepiandrostendione in men and women. Cancer Lett 1979; 7: 273-282.
81. Franceschi S. Fat and prostate cancer. Epidemiology 1994; 5: 271-273.
82. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 1975; 15: 617-631.
83. Carroll KK, Khor HT. Dietary fat in relation to tumorigenesis. Prog Biochem Pharmacol 1975; 10: 308-353.
84. Ross RK, Shimizu H, Paganini-Hill, et al. Case-control studies of prostate cancer in blacks and whites in Southern California. J Natl Cancer Inst 1987; 78: 869-874.
85. West DW, Slattery ML, Robinson LM, et al. Adult dietary intake and prostate cancer risk in Utah: a casecontrol study with special emphasis on aggressive tumors. Cancer Causes Control 1991; 2: 85-94.
86. Walker ARP, Walker BF, Tsotetsi NG, et al. Case-control study of prostate cancer in black patients in Soweto, South Africa. Br J Cancer 1992; 65: 438-441.
87. Kolonel LN, Yoshizawa CN, Hankin JH. Diet and prostate cancer: a case-control study in Hawaii. Am J Epidemiol 1988; 127: 999-1.12.
88. Kolonel LN. Cancer patterns of four ethnic groups in Hawaii. J Natl Cancer Inst 1980; 65: 1.127-1.39.
89. Mishina T, Watanabe T, Araki H, et al. Epidemiological study of prostatic cancer matched pair analysis. Prostate 1985; 6: 423-436.
90. Rotkin ID. Studies in the epidemiology of prostate cancer: expanded sampling. Cancer Treat Rep 1977; 61: 173-180.
91. Talamini R, LaVecchia C, Decarli A, et al. Nutrition, social factors and prostatic cancer in the Northern Italian population. Br J Cancer 1986; 53: 817-821.
92. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244-250.
93. LeMarchand L, Kolonel LN, Wilkens LR, et al. Animal fat comsumption and prostate cancer: a prospective study in Hawaii. Epidemiology 1994; 5: 276-282.
94. Gann PH, Hennekes CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst 1994; 86; 281-286.
95. Schwarts GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990; 10: 1.307-1.12.
96. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993; 2: 467-472.
97. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a 25-dihydroxyvitamin D3. ancer Res 1992; 52: 515-520.
98. Finchman SM, Hill GB, Hanson J, et al. Epidemiology of prostate cancer: a case-control study. Prostate 1990; 17: 189-206.
99. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chron Dis 1979; 32: 563-576.
100. Thune I, Lund E. Physical activity and the risk of prostate and testicular cancer: a cohort study of 53,000 Norwegian men. Cancer Causes and Control 1994; 5: 549-556.
101. Albanes D, Blair A, Taylor PR. Physical activity risk of cancer in the NHANES I population. Am J Public Health 1989; 79: 744-750.
102. Paffenbarger RS, Hyde RT, Wing AL. Physical activity and incidence of cancer in diverse populations: a preliminary report. Am J Clin Nutr 1987; 45: 12-17.
103. Severson RK, Nomura AMY, Grove JS, et al. A prospective analysis of physical activity and cancer. Am J Epidemiol 1989; 130: 522-529.
104. LeMarchand LL, Kolonel LN, Yoshizawa CN. Lifetime occupational physical activity and prostate cancer risk. Am J Epidemiol 1991; 133: 103-111.
105. Hsing AW, McLaughlin JK, Zheng W, et al. Occupation, physical activity and risk of prostate cancer in Shangai, People's Republic of China, Cancer Causes Control 1994; 5: 136-140.
106. Steele R, Lees REM, Kraus AS, et al. Sexual factors in the epidemiology of cancer of the prostate. J Chron Dis 1971; 24: 29-37.
107. Krain LS. Epidemiologic variables in prostatic cancer. Geriatrics 1973; 28: 93-98.
108. Jackson MA, Kovi J, Heshmat MY, et al. Characterization of prostatic carcinoma among blacks: a comparison between a low incidence area, Ibadan, Nigeria and a high incidence area, Washington, USA. Prostate 1980; 1: 185-205.
109. Honda GD, Bernstein L, Ross RK, et al. Vasectomy, cigarette smoking and age of first sexual intercourse as risk factors for prostate cancer in middle-age men. Br J Cancer 1988; 57: 326-331.
110. Heshmat MY, Kovi J, Herson J, et al. Epidemiologic association between gonorrhea and prostatic carcinoma. Urology 1975; 6: 457-460.
111. Less REM, Steele R, Erdle D. Arsenic, syphilis, and cancer of prostate J Epidemiol Commun Med 1985; 39: 227-230.
112. Mandel JS, Schuman LN. Sexual factors and prostatic cancer. Results from a case-control study. J Gerontol 1987; 42: 259-264.
113. Ross RK, Paganini-Hill A, Henderson BE. The etiology of prostate cancer: what does the epidemiology suggest? Prostate 1983; 4: 333-344
114. Ross RK, Deapen DM, Casagrande JY, et al. A cohort study of mortality from cancer of the prostate in catholic priests. Br J Cancer 1981; 43: 233-235.
115. Sanford EJ, Geder L, Laychock A, Rohner TJ, Rapp F. Evidence for the association of cytomegalovirus with carcinoma of the prostate. J Urol 1977; 118: 789-792.
116. Kinson GA, Layberry RA. Long-term endocrine responses to vasectomy in the adult rat. Contraception 1975; 11: 143-149.
117. Pierrepoint CG, Davies P. The effect of vasectomy on the activity of prostatic RNA polymerase in rats. J Reprod Fertil 1973; 35: 149-152.
118. Naik VK, Joshi UM, Sheith AR. Long term effects of vasectomy on prostatic function in men. J Reprod Fertil 1980; 58: 289-293.
119. Johnsonbaugh RE, O'Connell K, Engel SB, et al. Plasma testosterone, luteinizing hormone, and follicle stimulating hormone after vasectomy. Fertil Steril 1975; 26: 329-330.
120. Purvis K, Saksena SK, Cekan Z, et al. Endocrine effects of vasectomy. Clin Endocrinol 1976; 5: 263-272.
121. Smith KD, Tcholakian RK, Chowdhury M, et al. Endocrine studies in vasectomized men. En: Lepow IH, Crozier R, eds. Vasectomy: immunologic and pathophysiologic effects in animals and man. New York: Academic Press, 1979: 183-197.
122. Rosenberg L, Palmer JR, Zauber AG, et al. Vasectomy and risk of prostate cancer. Am J Epidemiol 1990; 132: 1.051-1.55.
123. Mettlin C, Natarajan N, Ruberm R. Vasectomy and prostate cancer risk. Am J Epidemiol 1990; 132: 1.056-1.61.
124. Hayes RB, Pottern LM, Greenberg R, et al. Vasectomy and prostate cancer in US blacks and whites. Am J Epidemiol 1993; 137: 263-269.
125. Giovannucci E, Ascherio A, Rimm E, et al. A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993; 269: 873-877.
126. Giovannucci E, Ascherio A, Rimm E, et al. A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 1993; 269: 878-882.
127. Sidney S. Vasectomy and the risk of prostatic cancer and benign prostatic hypertrophy. J Urol 1987; 138: 795-797.
128. American Urological Association. Position Statement. Cancer Epidemiol Biomarkers Prev 1993; 2: 295.
129. Wynder EL, Mabuchi K, Whitmore WF. Epidemiology of cancer of the prostate. Cancer 1971; 28: 344-360.
130. Woolf CM. An investigation on the familial aspects of cancer of the prostate. Cancer 1960; 13: 739-743.
131. Ghadirian P, Cadotte M, Lacroix A, et al. Familial aggregation of cancer of the prostate in Quebec: the top of the iceberg. Prostate 1991; 19: 43-52.
132. Spitz MR, Curriet RD, Fueger JJ, et al. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146: 1.304-1.07.
133. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
134. Grönberg H, Damber L, Damber JE, Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol 1997; 146: 552-557.
135. Steinberg GD, Carter BS, Beaty TH, et al. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-347.
136. Rodríguez C, Calle E, Miracle-MCMahill HL, et al. Family history and risk of fatal prostate cancer. Epidemiology 1997; 8: 653-657.
137. Greenwald P, Damon A, Kirmss V, et al. Physical and demographic features of men before developing cancer of the prostate. J Natl Cancer Inst 1974; 53: 341-346.
138. Hammarsten J, Anderson S, Holmen A, et al. Does transurethral resection of a clinically benign prostate gland increase the risk of developing clinical prostate cancer? Cancer 1994; 74: 2.347-2.51.
139. McNeal JE. Prostatic microcarcinomas in relation to origin and the evolution to clinical cancer. Cancer 1993; 71: 984-991.
140. Bostwick DG, Cooner WH, Denis L, et al. The association of benign prostatic hyperplasia and cancer of prostate. Cancer 1992; 70: 291-301.
141. Aldercreutz N. Hepatic metabolism of estrogen in health and disease. N Engl J Med 1974; 290: 1.081-1.83.
142. Siiteri PR, MacDonald P. Role of extraglandular estrogen in human endocrinology. En: Greep RD, ed. Handbook of physiology. Sect 7, Vol 12, Part 1. Washington DC: American Physiological Society, 1973: 615-629.
143. Pell S, D'Alonzo CA. A five year mortality study of alcoholics. J Occup Med 1973; 15: 120-125.
144. Monson RJ, Lyon JL. Proportional mortality among alcoholics. Cancer 1975; 36: 1.077-1.79.
145. Yu H, Harris RE, Wynder EL. Case-control study of prostate cancer and socioeconomic factors. Prostate 1988; 13: 317-325.
146. Tavani A, Negri E, Franceschi S, et al. Alcohol comsumption and risk of prostate cancer. Nutr Cancer 1994; 21: 25-31
147. Hayes RB, Brown LM, Schoenberg JB, et al. Alcohol use and prostate cancer risk in US blacks and whites. Am J Epidemiol 1996; 143: 692-697.
148. Dai WS, Kuller LH, LaPorte RE, et al. The epidemiology of plasma testosterone levels in middle-aged men. Am J Epidemiol 1981; 114: 804-816.
149. Barret-Conner E, Khaw KT. Smoking and endogenous sex hormones in men and women. En: Wald N, Baron J, eds. Smoking and hormone-related disorders. New York: Oxford University Press, 1990: 183-196.
150. Doll R, Peto R. Mortality in relation to smoking: 20 years observations on male British doctors. BMJ 1976; 2: 1.525-1.36.
151. Hammond EC. Smoking in relation to the death rates in one million men and women. Natl Cancer Inst Monogr 1966; 19: 127-204.
152. Rogot EM, Murray JL. Smoking and causes of death among US veterans: 16 years of observation. Public Health Rep 1980; 95: 213-222.
153. Kolonel L, Winkelstein W. Cadmium and prostatic carcinoma. Lancet 1977; ii: 566-567.
154. Armstrong BG, Kazantzis G. Prostatic cancer and chronic respiratory and renal disease in British cadmium workers: a case-control study. Br J Ind Med 1985; 42: 540-545.
155. Monson RJ, Nakano KK. Mortality among rubber workers. I. White male union employees in Akron, Ohio. Am J Epidemiol 1976; 103: 288-296.
156. Monson RJ, Nakano KK. Mortality among rubber workers. II. Other employees. Am J Epidemiol 1976; 103: 297-303.
157. Andjelkovic D, Taulbee J, Symons M. Mortality experience of a cohort of rubber workers, 1964-73. Occup Med 1976; 18: 387-394.
158. Blair A, Fraumeni JF. Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 1978; 61: 1.379-1.84.
159. Hoar SK, Blair A. Death certificate case-control study of cancers of the prostate and colon and employment in the textile industry. Arch Environ Health 1984; 39: 280-283.
160. Dosemeci M, Hoover RN, Blair A, et al. Farming and prostate cancer among African-Americans in the southeastern United States. J Natl Cancer Inst 1994; 86: 1.718-1.19.
161. Ernster VL, Selvin S, Brown SM, et al. Occupation and prostatic cancer: a review and retrospective analysis based on death certificates in two California counties. J Occup Med 1979; 21: 175-183.
162. Checkoway H, DiFerdinando G, Hulka BS, et al. Medical, lifestyle, and occupational risk factors for prostate cancer. Prostate 1987; 10: 79-88.
163. Blair A, Malker H, Canton KP, et al. Cancer among farmers: a review. Scand J Work Environ Health 1985; 11: 397-407.
164. Pearce EN, Sheppard RA, Fraser J. Case-control study of occupation and cancer of the prostate in New Zealand. J Epidemiol Commun Health 1987; 41: 130-132.
165. Von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Society Guidelines for the early detection of prostate cancer. Update, June 10, 1997. Cancer 1997; 80: 1.805-1.07.